ABSTRACT

Objective: To investigate the association of the BRAFV600E mutation with papillary thyroid carcinoma using clinical, morphological and prognostic parameters. We also intend to assess the utility of the BRAFV600E immunohistochemistry and compare it with BRAF polymerase chain reaction (RT-PCR).

Material and Method: We applied BRAFV600E immunohistochemistry in a cohort of 107 papillary carcinomas, 19 adenomas and 13 normal thyroid tissues that was chosen retrospectively between 2011 and 2015. Statistical analysis was based on semiquantitative immunohistochemistry findings. We also applied BRAF RT-PCR in a subgroup of 14 papillary carcinomas, 13 metastatic lymph nodes and 4 adenomas that was chosen randomly.

Results: In regard to the comparison of BRAFV600E immunohistochemistry and BRAF RT-PCR, a 3+ nuclear and cytoplasmic immunoeexpression was considered ‘positive’. The BRAFV600E mutation was most frequently observed in classic variant cases. No mutation was detected in follicular variant cases. The mutational status of the primary tumour and the lymph node metastasis was consistent. A significant relationship of the BRAFV600E mutation was found with prognostic factors such as higher pT stage, classic variant, lymphatic invasion, perineural invasion, lower mitotic index, lack of tumour capsule, intrathyroidal spread and extrathyroidal extension.

Conclusion: Immunohistochemistry, using the VE1 clone, is a reliable technique for detection of the BRAFV600E mutation. Our results with immunohistochemistry are consistent with a previous effort. In our study, despite the correlation between some pathological prognostic parameters and the BRAFV600E mutation; poor prognosis was found to be irrelevant overall. Morphological parameters seem to be keener than the BRAFV600E mutation. Nevertheless, different series display different results, possibly due to environmental factors. Considering this and the proven success of targeted therapies against the BRAFV600E mutation a thorough assessment would be important.

Key Words: Thyroid, Papillary carcinoma, BRAFV600E, Immunohistochemistry, Reverse Transcriptase PCR, Prognosis

INTRODUCTION

Papillary carcinoma of the thyroid (PTC) is one of the most common cancers with an incidence rate of 14.42 per 100 000 person-years in 2010–2013 (1). PTCs have been known to have a better prognosis than other malignant tumours of the human body, although around 10% exhibit a worse clinical course than expected in PTCs. Several immunohistochemical stains have been used, such as cytokeratin 19 (CK19), Hector Battifora mesothelial cell-1 (HBME-1) and Galectin-3, to diagnose and detect this small group. The rapid development in molecular pathology has led to deeper efforts in coming up with the privileges of targeted therapy options.

The most relevant genetic alterations in PTC are generally mutually exclusive and in the vast majority of cases cause activation of the MAPK pathway; such as BRAF, RET and RAS mutations with BRAF mutations in the centre of attention (2). Mutations affecting the BRAF proto-oncogene are point mutations, small in-frame deletions, insertions and chromosomal rearrangements; the most frequent of which is the BRAFV600E point mutation. As a group, BRAF mutations activate RAF kinase and lead to chronic stimulation of the mitogen-activated protein kinase pathway. In PTCs, BRAF mutations have been postulated as a cause of tumour recurrence (3) and worse prognosis (4, 5), along with initial tumour pathogenesis.

Correspondence: Faruk Erdem KOMBAK
Marmara University, School of Medicine, Department of Pathology, İSTANBUL, TURKEY
E-mail: erdemkombak@hotmail.com    Phone: +90 533 379 35 08
chain reaction (RT-PCR) and Sanger sequencing are the gold standard techniques to detect BRAFV600E mutation, whereas immunohistochemistry (IHC) needs more scientific evidence of high specificity and sensitivity. Some morphological findings like multicity, lymph node metastasis, tumour extension beyond the thyroid parenchyma and Psammoma bodies (6) may also predict the BRAFV600E mutation.

CK19 is a low molecular weight cytokeratin found in simple and complex epithelia, as well as in some carcinomas. An increased intensity of CK19 immunostaining is used for the diagnosis of PTC. HBME-1 is a marker of the apical surface of the mesothemium. An apical membranous staining of HBME-1 is also seen in PTCs. Galectin-3 is a β-galactoside binding lectin in charge of cell adhesion. Nuclear and cytoplasmic immunostaining is seen in PTCs. Ki-67 detects the nuclei of cells in late G1, S, G2 and M phases. Proliferation index in PTCs is no more than 5% in general (7).

The aim of this study is to evaluate the immunoexpression of BRAFV600E, and its correlation with clinicopathologic parameters.

MATERIALS and METHODS

The study involved the use of formalin-fixed paraffin-embedded tissue sections of histopathologically diagnosed cases of PTC (n = 107) and adenoma (n = 19) from the archives of the Department of Pathology. Of the PTC cases, 23 were microcarcinomas; 2 were follicular variants, 1 was oncocytic and 20 were classic. Twenty-three of the PTC group had metastatic lymph nodes available. These lymph nodes were assessed similarly. The slides that had been routinely stained with hematoxylin and eosin, CK19, HBME-1, Galectin-3 and Ki-67 were re-evaluated. The PT stage, necrosis, calcification, lymphatic invasion, vascular invasion, perineural invasion, tumour capsulation and capsule invasion, extrathyroidal extension, multicentricity, intrathyroidal spread and surgical margin status were assessed as prognostic parameters. To avoid controversy, certain criteria were used (8) as elaborated below.

Vascular invasion was defined as a direct tumour extension into the blood vessel lumen or a tumour aggregate within the vessel lumen. The criteria for vascular invasion are as follows:

- The affected vessel must be located within the capsule or immediately beyond the capsule but not within the tumour nodule itself.
- The vessel should have a clearly identifiable wall with endothelial lining.
- If a tumour extends directly into the vessel lumen, it should form a polypoid mass protruding into the lumen or exhibit thrombus formation in association with the tumour and not just bulging into the lumen.
- The cell aggregates within the lumen should be histologically identical to the tumour cells and be composed of epithelial cells and not of reactive endothelial cells.
- The intravascular tumour aggregate should be attached to the wall of the blood vessel and covered by a layer of endothelial cells.

Extrathyroidal extension was defined as tumour penetration through the thyroid pseudocapsule into the adjacent skeletal muscles or other organs.

Intrathyroidal spread was defined as an intraglandular dissemination of a tumour via lymphatic channels, and multiple small or larger satellite foci in the vicinity or remotely from the main tumour mass.

Information regarding the gender and age of the patients was obtained from the automation system of our hospital. Clinical follow-up was provided by the general surgery department. PTC cases were classified as either ‘good prognosis (GP)’ or ‘poor prognosis (PP)’ upon the clinical occurrence of lymph node metastasis, local recurrence and/or distant metastasis. Clinicopathologic features are shown in Table I. Serial sections (4 µm thick) were obtained from the paraffin-embedded blocks of the selected preparations and fixed on positively charged slides to perform IHC. BRAFV600E IHC was performed manually using the Novolink™ Polymer Detection System (Leica, Australia). Additional information on IHC is summarised in Table II. Positive and negative control slides were also stained. All 31 cases (14 primary tumours (PT), 13 metastatic lymph nodes and 4 adenomas) were selected randomly, and BRAF mutation analysis was performed on these cases using the Cobas® 4800 RT-PCR System (Roche Diagnostics, USA).

Assessment of Immunostaining

The assessment of BRAFV600E IHC in PTCs, melanomas and colonic adenocarcinomas is still under debate (9). However, in our study, nuclear with or without cytoplasmic staining was considered positive as in most of the literature. A semiquantitative approach was used based on the staining intensity of positively stained cells: negative, 1+ (weak staining), 2+ (moderate staining) and 3+ (strong staining) of any proportion of tumour cells (Figures 1-4). Any proportion of tumour cells with membranous and cytoplasmic staining with CK19, apical...
membranous staining with HBME-1 and nuclear and/or cytoplasmic staining with Galectin-3 was considered positive. The eyeballing technique was used for the Ki-67 labelling index, and 100 tumour cells were counted in hot spot areas. A proportion of nuclear-stained cells with Ki-67 was recorded and divided into groups with a threshold of 5%.

**Statistical Analysis**

Statistical assessments were performed using the SPSS software (SPSS version 15, SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean ± standard deviation together with a range (minimum–maximum). The comparison of categorical variables was performed using the chi-square test. Fisher’s exact test was used to compare BRAFV600E IHC and RT-PCR. A *P*-value of less than 0.05 was accepted as statistically significant.

**Table 1: Clinicopathologic features of the cases in the PTC group.**

| Gender          | Male 22% (n = 24) | Female 78% (n = 83) |
|-----------------|-------------------|---------------------|
| Mean age        | 44 years          |
| Type of resection | Total thyroidectomy 44% (n = 47) | Lobectomy 56% (n = 60) |
| Surgical margins | Positive 23% (n = 25) | Negative 77% (n = 82) |
| Clinical follow-up | Available 91% (n = 97) | N/A 9% (n = 10) |
| Mean follow-up time | 25 months        |
| Survival        | Alive 99% (n = 106) | Dead 1% (n = 1) |
| Lymph node metastasis | Synchronous 24% (n = 26) | Later 1% (n = 1) |
|                 | Local recurrence 5% (n = 5) | Distant metastasis 2% (n = 2) |
| Prognostic group | Good prognosis 68% (n = 73) | Poor prognosis 32% (n = 34) |

PTC: Papillary carcinoma of the thyroid.
RESULTS

Of the PTC cases, 43% (n = 46) was pT1, 27% (n = 29) pT2 and 30% (n = 32) pT3. The mean tumour size was 20.98 mm (min. 3 mm and max. 75 mm) in PTCs and 25.79 mm (min. 9 mm and max. 67 mm) in adenomas. Of the PTC cases, 45% (n = 48) was classic variant, 23% (n = 25) follicular, 10% (n = 11) oncocytic and 22% (n = 23) microcarcinomas (Figures 5-8). Of the microcarcinomas, 87% (n = 20) was classic variant, 9% (n = 2) follicular and 4% (n = 1) oncocytic. Of the adenomas, 15.8% (n = 3) was oncocytic.

Twelve of the PTC cases were negative for HBME-1, one was negative for CK19 and six were negative for Galectin-3. In BRAFV600E IHC, 31 of the PTC cases were negative. Twelve cases showed a Ki-67 proliferation index higher than 5%. For BRAFV600E IHC, positive cases exhibited varying percentages of staining as shown in Table III.

The results of BRAF RT-PCR of randomly selected cases are shown in Table IV. For comparison of IHC and RT-PCR, the highest likelihood ratio (8.18) was obtained with the hypothesis ‘Only 3+ IHC of BRAFV600E is truly positive’. The sensitivity of BRAFV600E IHC was calculated at 90.9%, whereas the specificity was 88.8%. In addition, the positive predictive value was 95.2%, and the negative predictive value was 80%. Given the likelihood ratio at 8.18, 1 of every 10 tests was meant to be wrong. In this respect, the BRAFV600E IHC findings are reconsidered and summarised in Table V.

Table II: Details of immunohistochemical findings.

| Antibody   | Clone                      | Dilution | Incubation time (min) | Temperature (°C) |
|------------|----------------------------|----------|-----------------------|------------------|
| BRAFV600E  | VE-1 (mm); Spring Bioscience | 1/100    | 60 (manual)           | 37               |
| CK19       | AB53 (mm); Dako             | 1/100    | 30 (Bond-Max)         | 56               |
| HBME-1     | HBME-1 (mm); Dako           | 1/50     | 30 (Bond-Max)         | 56               |
| Galectin-3 | 9C4 (mm); Dako              | 1/100    | 30 (Bond-Max)         | 56               |
| Ki-67      | SP6 (rm); Abcam             | 1/100    | 30 (Bond-Max)         | 56               |

IHC: Immunohistochemistry, mm: Mouse monoclonal, rm: Rabbit monoclonal.

Figure 4: BRAFV600E IHC 3+ (x200).

Figure 5: Classic variant papillary carcinoma (H&E; x200).

Figure 6: Follicular variant papillary carcinoma (H&E; x200).
### Table III: BRAFV600E IHC.

| Group                   | 0  | 1+ | 2+ | 3+ | Total |
|-------------------------|----|----|----|----|-------|
| PTC-classic             | 11 | 3  | 7  | 27 | 48    |
| PTC-follicular          | 13 | 11 | 1  | 0  | 25    |
| PTC-oncocytic           | 2  | 5  | 3  | 1  | 11    |
| Papillary microcarcinoma| 5  | 3  | 9  | 6  | 23    |
| Adenoma                 | 12 | 7  | 0  | 0  | 19    |
| Normal thyroid tissue   | 2  | 10 | 1  | 0  | 13    |
| Total                   | 45 | 39 | 21 | 34 | 139   |

IHC: Immunohistochemistry, PTC: Papillary carcinoma of the thyroid.

### Table IV: BRAF RT-PCR results.

| IHC (−)  | IHC (1+) | IHC (2+) | IHC (3+) | Total |
|----------|----------|----------|----------|-------|
| RT-PCR (−) | 10       | 5        | 5        | 1     | 21    |
| RT-PCR (+)  | 1        | 0        | 1        | 8     | 10    |
| Total       | 11       | 5        | 6        | 9     | 31    |

RT-PCR: Polymerase chain reaction, IHC: Immunohistochemistry.

### Table V: BRAFV600E IHC upon RT-PCR results.

| Group                   | 0/1+/2+  | 3+        | Total |
|-------------------------|----------|-----------|-------|
| PTC-classic             | 21       | 27 (59.5) | 48    |
| PTC-follicular          | 25       | 0 (0)     | 25    |
| PTC-oncocytic           | 10       | 1 (9)     | 11    |
| PMC                     | 17       | 6 (26)    | 23    |
| Total                   | 73       | 34 (31.8) | 107   |

IHC: Immunohistochemistry, RT-PCR: Polymerase chain reaction, PTC: Papillary carcinoma of the thyroid, PMC: Papillary microcarcinoma.

---

**Figure 7:** Oncocytic variant papillary carcinoma (H&E; x200).

**Figure 8:** Papillary microcarcinoma (H&E; x40).
In cases where a metastatic lymph node (MLN) is present, the \textit{BRAFV600E} positivity was 11\% in PT. Two of those showed no staining in MLN, whereas PT was positive. Another two cases showed a lower percentage of positive tumour cells in MLN (Table VI). However, PTs and conjugate MLNs were statistically correlated upon the \textit{BRAFV600E} mutation ($\phi = 83.7\%$, $p = 0.0001$).

The \textit{BRAFV600E} mutation was found to be statistically correlated with a higher pT stage ($p = 0.003$), classic morphology ($p = 0.003$), lower mitotic index ($p = 0.020$), lymphatic invasion ($p = 0.013$), perineural invasion ($p = 0.006$), a lack of tumour capsule ($p = 0.016$), extrathyroidal extension ($p = 0.0001$) and intrathyroidal spread ($p = 0.0001$). No association was found between the \textit{BRAFV600E} mutation and the patient’s age, sex, synchronous lymph node metastasis, necrosis, calcification, vascular invasion, tumour capsule invasion, multicentricity, expressions of CK19, HBME-1, and Galectin-3 and the Ki-67 proliferation index. Of the \textit{BRAFV600E}-mutated cases, 52.9\% exhibited nodular hyperplasia in the non-tumoural parenchyma, whereas 23.5\% showed lymphocytic thyroiditis. Neither had a significant association.

The clinical prognosis was assessed in two separate groups as described earlier. The poor prognostic group was found to be statistically correlated with a higher pT stage ($p = 0.005$), classic morphology ($p = 0.011$), calcification ($p = 0.017$), lymphatic invasion ($p = 0.008$), vascular invasion ($p = 0.0001$), lack of tumour capsule ($p = 0.004$), extrathyroidal extension ($p = 0.0001$), intrathyroidal spread ($p = 0.001$) and positive surgical margin ($p = 0.002$). No association was found with the patient’s age, sex, necrosis, mitotic index, perineural invasion, tumour capsule invasion and multicentricity. HBME-1 positive cases were found to be correlated with PP ($p = 0.049$), whereas CK19 expression, Galectin-3 expression and Ki-67 proliferation index were irrelevant.

| Case | PT-\textit{BRAF} | PT-\textit{BRAF}-\% | MLN-\textit{BRAF} | MLN-\textit{BRAF}-\% |
|------|-----------------|------------------|-----------------|------------------|
| 1    | Negative        |                  |                 |                  |
| 2    | Positive        | 90               | Positive        | 90               |
| 3    | Positive        | 80               | Positive        | 70               |
| 4    | Negative        |                  |                 |                  |
| 5    | Positive        | 100              | Negative        |                  |
| 6    | Negative        |                  |                 | Negative         |
| 7    | Negative        |                  |                 | Negative         |
| 8    | Positive        | 100              | Positive        | 100              |
| 9    | Negative        |                  |                 | Negative         |
| 10   | Positive        | 90               | Positive        | 40               |
| 11   | Negative        |                  |                 | Negative         |
| 12   | Negative        |                  |                 | Negative         |
| 13   | Negative        |                  |                 | Negative         |
| 14   | Negative        |                  |                 | Negative         |
| 15   | Positive        | 100              | Positive        | 100              |
| 16   | Negative        |                  |                 | Negative         |
| 17   | Positive        | 90               | Positive        | 90               |
| 18   | Positive        | 100              | Positive        | 100              |
| 19   | Negative        |                  |                 | Negative         |
| 20   | Positive        | 100              | Positive        | 100              |
| 21   | Positive        | 100              | Positive        | 100              |
| 22   | Positive        | 100              | Negative        |                  |
| 23   | Negative        |                  |                 | Negative         |

\textit{PT-\textit{BRAF}}: \textit{BRAFV600E} mutation in primary tumour, \textit{PT-\textit{BRAF}}-\%: Percentage of \textit{BRAFV600E} positive cells in primary tumour, \textit{MLN-\textit{BRAF}}: \textit{BRAFV600E} mutation in conjugate metastatic lymph node, \textit{MLN-\textit{BRAF}}-\%: Percentage of \textit{BRAFV600E} positive cells in conjugate metastatic lymph node, \textit{PT}: Primary tumour, \textit{MLN}: Metastatic lymph node.
In cases where the BRAFV600E mutation was present, poor prognostic incidents such as lymph node metastasis, local recurrence and distant metastasis were more frequent. However, we could not reveal any statistical significance \((p = 0.255)\). On the other hand, BRAFV600E positive cases constituted a minority of 40% in the poor prognostic group.

**DISCUSSION**

PTCs are malignant tumours with an increasing incidence rate (1). The widespread use of radiological techniques and fine-needle aspiration biopsy has been partly responsible for this increasing incidence, although the vast majority of new cases are microcarcinomas (10). Lobectomy or total thyroidectomy with subsequent radioactive iodine ablation in selected patients is usually more effective; however, approximately 10% of PTC patients suffers from recurrence, lymph node or distant metastasis and hence require further intervention. BRAF mutations are the major promising development for PTC recently, providing a highly efficient anti-tyrosine kinase therapy.

Several studies have compared BRAFV600E IHC with molecular techniques. For instance, Qiu et al. (11) assessed BRAFV600E IHC by distinguishing samples as positive and negative without considering staining intensity and percentage of stained tumour cells. The study also compared IHC with RT-PCR and Sanger sequencing. Jung et al. (12) also compared IHC with RT-PCR and BRAF RNA in situ hybridisation. Zagzag et al. (13) accepted 3+ BRAFV600E staining as positive and compared IHC with direct sequencing. Ilie et al. (14) accepted the results as positive if 100% of the tumour cells stained 3+ and compared IHC with direct sequencing. To sum up, the sensitivity and specificity of BRAFV600E IHC ranges from 89% to 100% and from 61% to 100%, respectively. In our study, we accepted 3+ BRAFV600E staining as positive, disregarding the percentage of tumour cells, and compared IHC with RT-PCR. The sensitivity of BRAFV600E IHC was 90.9%, whereas the specificity was 88.8%. It is important to note that the RT-PCR system we used detects V600D and V600K mutations along with V600E, thus giving a non-discriminatory result.

Using the criteria 3+ nuclear and cytoplasmic staining in the PTC group, the BRAFV600E mutation rate was 31.8%. This rate increased up to 59.5% in classic variant cases, but it decreased to 26% in papillary microcarcinomas (PMCs) and 9% in oncocytic variant cases. In follicular variant and adenoma cases, no mutation was detected. In the recent literature, the BRAFV600E mutation rate has been reported between 35% and 70%, and the mutations were more often associated with a classic variant, tall cell variant and poorly differentiated/anaplastic carcinomas that arise from well-differentiated PTCs (15). The mutation rate is much lower in follicular PTCs (16), which is similar to our results.

Intratumoural heterogeneity is a substantial phenomenon for understanding pathogenesis and its clinicopathologic role. As in other BRAF-harbouring tumours such as malignant melanomas and colorectal and pulmonary adenocarcinomas, PTCs have been shown to exhibit heterogeneously mutated tumour cells. Guerra et al. (17) showed BRAF-mutated tumour cells in MLNs of cases with BRAF negative primary, prompting that BRAF mutations constitute a subclonal alteration and may arise de novo in BRAF negative tumours later on. On the other hand, de Biase et al. (16) revealed a direct proportion between tumour size and percentage of BRAF-mutated tumour cells, suggesting that BRAF mutation is an early period alteration. Walts et al. (18) stated 100% concordance of BRAF mutation between PT and MLN and 92.3% concordance between different areas of PTs. In their experience, two BRAF-mutated PT cases exhibited BRAF-negative MLNs and recurrent tumours afterward. We observed a range of 80–90% BRAF-mutated tumour cells in PTs, two of which exhibited BRAF-negative MLNs and the other two showed a lower percentage of BRAF-mutated tumour cells in conjugated MLNs. The existence of such subclones disturbs the efficacy of targeted therapies. In this regard, quantitative BRAF mutation analysis may be suggested in PT, MLN, distant metastasis or recurrent tumour samples.

To start with associations between the BRAFV600E mutation and clinicopathologic parameters, we found no association with the patient’s age and sex, as in the large-scale meta-analysis of Wang et al. (19) and series of Shin et al. (20). In our experience, BRAFV600E mutation was found to be correlated with a higher pT stage, lymphatic invasion, perineural invasion, lack of tumour capsule, extrathyroidal extension and intrathyroidal spread. Several studies have stated various morphological findings, and their combinations are correlated with the BRAFV600E mutation, interestingly having extrathyroidal extension in common (6,21,22).

Surprisingly, the BRAFV600E mutation rate was higher in tumours with a lower mitotic index, as in tumours with a lower Ki-67 proliferation index, despite its incoherency. No effort has been found in the English literature that addresses the association between BRAF mutations and mitotic index or the Ki-67 proliferation index. Nevertheless, well-differentiated PTCs are known to have a lower proliferation index than other malignancies. We observed that the Ki-67
proliferation index is higher than 5% in 19.6% of the PTC cases, reaching up to 15%. In addition, we did not find any significant association between mitotic/Ki-67 index and worse clinical and/or pathologic prognostic parameters. Guerra et al. (23) showed a higher rate of CK19 expression in BRAF-mutated tumours, whereas Galectin-3 was not associated with BRAF. In terms of HBME-1 expression and BRAF, our effort needs to be published first. However, in our series, no significant association was found between the BRAFV600E mutation and expression of CK19, Galectin-3, and HBME-1.

In cases where follow-up data are available, a survival analysis could not be made because there was no death by disease. The cases were assessed in two separate groups: GP and PP, as described earlier. The patient's age and sex were not found to be correlated with the prognosis. This is despite the fact that Howell et al. (24) stated that the BRAFV600E mutation and older age (≥ 65 years) predict recurrence and Suman et al. (25) associated younger age (≤ 45 years) with central lymph node metastasis.

In our series, PP was found to be associated with a higher pT stage, classic morphology, calcification, lymphatic invasion, vascular invasion, lack of tumour capsule, intrathyroidal spread, extrathyroidal extension, positive surgical margin and loss of HBME-1 expression. Likewise, Rossi et al. (26) have associated PP in poorly differentiated and anaplastic thyroid carcinomas with loss of HBME-1 expression.

The association between the BRAFV600E mutation and PP can be properly summarised by the meta-analysis of Wang et al. (19). In contrast to what has been reported recently, Pelttari et al. (27), with their lengthy follow-up duration, have shown that the BRAFV600E mutation is not correlated with lymph node metastasis and/or recurrence. Zheng et al. (28) have revealed that the BRAFV600E mutation and the recurrence within PMCs are not related. Nam et al. (21) have also shown that the BRAFV600E mutation is not significantly associated with lymph node metastasis. In these series, despite the overall concern, some morphological findings such as extrathyroidal extension are interestingly correlated with the BRAFV600E mutation. For instance, Shin et al. (20) revealed that the BRAFV600E mutation does not seem to be associated with the overall prognosis but morphological parameters are associated solely and together with aggressive behaviour. We also did not find any association between the BRAFV600E mutation and the overall prognosis but with such morphologic parameters.

In conclusion, BRAFV600E IHC with VE1 clone can be accepted as a reliable technique for detecting the BRAFV600E mutation. Our series of well-differentiated PTCs has exhibited a rate of BRAFV600E mutation similar to recent literature. With our effort, morphological findings may be considered keener than the BRAFV600E mutation in predicting aggressive behaviour. However, demographic, clinical and morphological findings and genetic alterations should be assessed together to estimate a more precise prognosis. Although further therapeutic interventions are needed, it is better to look for the BRAFV600E mutation in PT, lymph node metastasis, recurrent tumour and distant metastasis, if available.

ACKNOWLEDGEMENT

We would like to express our sincere gratitude to Prof. Nural Bekiroğlu (Marmara University, School of Medicine, Department of Biostatistics) for her supervision in our statistical assessments.

CONFLICT of INTEREST

All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

FUNDING

This work was supported by the BAP (Scientific Research Projects Unit of Marmara University, grant number SAGC-TUP-121114-0357).

REFERENCES

1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317:1338-48.
2. Lloyd RV, Osamura RY, Klöppel G, Rosai J, Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lloyd RV, Osamura R, Klöppel G, Rosai J, editors. Lyon: International Agency for Research on Cancer; 2017.
3. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O’Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42-50.
4. Niederer-Wust SM, Jochem W, Forbs D, Brandle M, Bilz S, Clerici T, Oettli R, Müller J, Haile SR, Ess S, Stoeckli SJ, Brogli MA. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery. 2015;157:119-25.
5. Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S. BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer. 2015;22:159-68.

90
6. Virk RK, Theoharis CG, Prasad A, Chhieng D, Prasad ML. Morphology predicts BRAF(V600E) mutation in papillary thyroid carcinoma: An interobserver reproducibility study. Virchows Arch. 2014;464:435-42.

7. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedénius J. MIB-1 index in thyroid tumors: A predictor of the clinical course in papillary thyroid carcinoma. Thyroid. 2003;13:371-80.

8. Nikiforov YE, Biddinger PW, Thompson LD.R. Diagnostic Pathology and Molecular Genetics of the Thyroid Philadelphia: Wolters Kluwer; 2015. Available from: http://qut.eblib.com.au/patron/FullRecord.aspx?p=3417856.

9. Pyo JS, Sohn JH, Kang G. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma. Endocrine pathology. 2015;26:211-7.

10. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:47-53.

11. Qiu T, Lu H, Guo L, Huang W, Ling Y, Shan L, Li W, Ying J, Lv N. Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Scientific reports. 2015;5:9211.

12. Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS. Clinicopathologic correlations of the BRAF V600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathology, research and practice. 2015;211:162-70.

13. Zagzag J, Pollack A, Dulz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. 2015;159:198-204; discussion 1204-5.

14. Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P. Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in papillary thyroid carcinoma: Comparative analysis with three DNA-based assays. Thyroid. 2014;24:858-66.

15. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-404.

16. de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A, Tallini G. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J Clin Endocrinol Metab. 2014;99:E1530-8.

17. Guerra A, Sapiro MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzl G, Vitale M. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517-24.

18. Walts AE, Pao A, Sacks W, Bose S. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. Hum Pathol. 2014;45:935-41.

19. Wang Z, Chen JQ, Liu JL, Qin XG. Clinical impact of BRAF mutation in the diagnosis and prognosis of papillary thyroid carcinoma: A systematic review and meta-analysis. Eur J Clin Invest. 2016;46:146-57.

20. Shin MK, Kim JW, Min SK, Lee DJ, Kim JH, Lee SC, Chung BW, Ju YS. Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients. Oncol Lett. 2015;10:1882-8.

21. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203:436-41.

22. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20:47-52.

23. Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Calio A, Zeppa P, Esposito S, Fulciniti F, Vitale M. BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine. 2013;44:165-71.

24. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L. Both BRAF V600E mutation and older age (>\=/ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011;18:3566-71.

25. Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA, Winchester DJ. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: A National Cancer Data Base (NCDB) study. Surgery. 2016;159:31-40.

26. Rossi ED, Straccia P, Palumbo M, Stigliano E, Revelli L, Lombardi CP, Santeseusano G, Pontecorvi A, Fadda G. Diagnostic and prognostic role of HBME-1, galectin-3, and beta-catenin in poorly differentiated and anaplastic thyroid carcinomas. Appl Immunohistochem Mol Morphol. 2013;21:237-41.

27. Pelttari H, Schlain-Jantti C, Arola J, Loyttyneniemi E, Knuutila S, Valimaki MJ. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS. 2012;120:380-6.

28. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M. Papillary microcarcinoma of the thyroid: Clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013;20:2266-73.